In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on MoonLake Immunotherapeutics, with a price target of $75.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rami Katkhuda has given his Buy rating due to a combination of factors surrounding MoonLake Immunotherapeutics’ recent developments and future potential. Despite the mixed results from the VELA program, where sonelokimab did not achieve statistical significance on HiSCR75 in VELA-2 due to a higher-than-expected placebo response, the drug still met all primary and secondary endpoints in VELA-1 and the overall program. This suggests a promising efficacy profile that could be advantageous in the large market for hidradenitis suppurativa.
Additionally, the favorable safety profile and convenient dosing regimen of sonelokimab, alongside the potential for regulatory and commercial success, contribute to the positive outlook. MoonLake’s pipeline also presents several upcoming catalysts, including clinical updates in other indications such as PPP, axSpA, adolescent HS, and PsA over the next twelve months. These factors combined indicate a strong potential for growth and justify the Buy rating.
Katkhuda covers the Healthcare sector, focusing on stocks such as VYNE Therapeutics, Eledon Pharmaceuticals, and Dianthus Therapeutics. According to TipRanks, Katkhuda has an average return of 30.4% and a 52.53% success rate on recommended stocks.